Allergan

FDA approves biodegradable implant for eye conditions

09-Mar-2020 By Ben Hargreaves

Allergan’s intracameral sustained-release implant receives US FDA approval for two indications treating ophthalmic conditions.

Sosei Heptares pulls dementia trial to minimize CRO expenditure

18-Nov-2019 By Nick Taylor

Sosei Heptares withdraws Phase II dementia with Lewy bodies trial to reduce spending on contract research while clinical activity is suspended.

Poll

Will pharma M&A keep up the pace in second half of 2019?

16-Aug-2019 By Ben Hargreaves

So far in 2019, there has been significant activity in M&A, particularly on the larger scale, but can the pace continue for the rest of the year?

AbbVie looks to post-Humira growth with $63bn Allergan buyout

25-Jun-2019 By Ben Hargreaves

AbbVie decides to move forward with a buyout of Allergan, after the latter company’s share price experienced a decline over recent years.

Hired and Retired: Resignations take industry by surprise

05-Apr-2019 By Ben Hargreaves

March saw significant changes within leadership roles across the industry, with more than one unexpected resignation.

Houston Methodist ups TriNetX network with 1.3m patients

28-Feb-2019 By Maggie Lynch

Houston Methodist Hospital joins the TriNetX global health research network to provide RWD for study feasibility and academic collaboration in industry-sponsored clinical trials.

Pfizer blockbuster patent felled by UK Supreme Court

14-Nov-2018 By Ben Hargreaves

Competitors will now be able to manufacture generic versions of Lyrica for the UK market, after the Supreme Court removed patent protection.

Allergan moves away from $200m plant expansion in Texas

05-Nov-2018 By Ben Hargreaves

The decision, influenced by the expected loss of exclusivity for Restasis, will allow the company to ‘improve efficiencies’ across its manufacturing network, a spokesperson explained.

Hired and Retired: Summer Edition

07-Sep-2018 By Ben Hargreaves

in-PharmaTechnologist gives you an overview of some of the notable hires that have taken place in the last month.

Allergan says ‘safety concerns’ prompted US FDA rejection

23-Aug-2018 By Flora Southey

The US FDA has vetoed Allergan’s ulipristal acetate candidate, designed for the treatment of abnormal uterine bleeding in women with uterine fibroids.